BioPorto Logo

BioPorto

An in vitro diagnostics company specializing in biomarkers for early kidney injury detection.

BIOPOR | CO

Overview

Corporate Details

ISIN(s):
DK0011048619
LEI:
5299004SWFL5JAN4W830
Country:
Denmark
Address:
Tuborg Havnevej 15, st., 2900 Hellerup

Description

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-24 10:37 Danish 34.3 KB
2025-11-24 10:37 English 32.7 KB
2025-11-24 10:37 Danish 566.4 KB
2025-11-24 10:37 English 527.4 KB
2025-11-24 10:09 English 7.4 KB
2025-11-24 10:09 Danish 520.8 KB
2025-11-24 10:09 Danish 7.4 KB
2025-11-24 10:09 English 500.5 KB
2025-11-13 19:50 English 12.3 KB
2025-11-13 19:50 Danish 545.9 KB
2025-11-13 19:50 English 511.2 KB
2025-11-13 19:50 Danish 12.2 KB
2025-11-04 22:10 Danish 225.4 KB
2025-11-04 22:10 English 238.1 KB
2025-11-04 22:10 English 18.9 KB

Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioPorto

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioPorto via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures biologic medicines, including biosimilars and novel drugs.
South Korea
007460
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.